Market news

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' equity of $1,075,007 as reported in the...

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026.The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com,...

Detailed price information for Inmed Pharmaceuticals Inc (INM-Q) from The Globe and Mail including charting and trades.

Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine therapies.

Gainers InMed Pharmaceuticals (NASDAQ:INM) stock moved upwards by 66.8% to $2.57 during Wednesday's pre-market session. The company's market cap stands at $8.2 million. China SXT Pharmaceuticals (NASDAQ:SXTC)

Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered into an amendment (the "Amendment") to the previously announced definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp., a...